11/7/2019 9:16:03 AM
William Blair Is Increasing Nektar Therapeutics (NKTR) FY21 Estimate To -3.22 From -4.41
11/7/2019 9:15:45 AM
William Blair Is Raising Nektar Therapeutics (NKTR) FY20 Estimate To -3.00 From -3.92
11/7/2019 9:14:16 AM
William Blair Is Increasing Nektar Therapeutics (NKTR) FY19 Estimate To -2.59 From -3.18
11/7/2019 8:52:44 AM
William Blair Reiterates Nektar Therapeutics (NKTR) At Outperform
11/6/2019 4:06:59 PM
Nektar Therapeutics Q3 Loss/share $0.56, Same As Last Year
10/16/2019 9:02:15 AM
Nektar Therapeutics Announces Initiation Of First-in-Human Phase 1 Clinical Study Of NKTR-255
10/7/2019 9:03:08 AM
Nektar Initiates 2 Studies Of Novel T Regulatory Cell Stimulator NKTR-358 In Patients With Psoriasis, Atopic Dermatitis
10/1/2019 8:03:34 AM
Nektar Therapeutics Promotes Gil Labrucherie To COO In Addition To His Role As CFO
9/26/2019 7:02:17 AM
Nektar Therapeutics Reports Presentation Of New Clinical Data For Bempegaldesleukin With Nivolumab
8/8/2019 4:25:20 PM
Nektar Therapeutics Q2 Loss/share $0.63 Vs. Profit $5.33 Year Ago
8/1/2019 7:24:38 AM
Nektar, Bristol-Myers Announce FDA Breakthrough Therapy Designation For NKTR-214 In Combination With Opdivo
6/13/2019 6:47:50 AM
Nektar Therapeutics Announces Results From Phase 1a Study Of NKTR-358 At Annual European Congress Of Rheumatology
6/1/2019 12:37:57 PM
Nektar Therapeutics Presents Biomarker And Clinical Data From PIVOT-02 Phase 2 Study Of Bempegaldesleukin With Nivolumab
5/23/2019 8:07:40 AM
Nektar Announces The Launch Of Inheris Biopharma